Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Current Assets (2018 - 2025)

Quantum Biopharma's Current Assets history spans 8 years, with the latest figure at $6.5 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 46.25% to $6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.5 million, a 46.25% decrease, with the full-year FY2025 number at $6.5 million, down 46.25% from a year prior.
  • Current Assets hit $6.5 million in Q4 2025 for Quantum Biopharma, down from $9.3 million in the prior quarter.
  • Over the last five years, Current Assets for QNTM hit a ceiling of $45.9 million in Q4 2021 and a floor of $6.5 million in Q4 2025.
  • Historically, Current Assets has averaged $14.7 million across 5 years, with a median of $10.7 million in 2023.
  • Biggest five-year swings in Current Assets: surged 70.97% in 2021 and later tumbled 61.14% in 2022.
  • Tracing QNTM's Current Assets over 5 years: stood at $45.9 million in 2021, then tumbled by 61.14% to $17.9 million in 2022, then tumbled by 37.9% to $11.1 million in 2023, then increased by 8.73% to $12.1 million in 2024, then crashed by 46.25% to $6.5 million in 2025.
  • Business Quant data shows Current Assets for QNTM at $6.5 million in Q4 2025, $9.3 million in Q3 2025, and $10.3 million in Q2 2025.